- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06522568
Tester une intervention décisionnelle par mammographie en milieu rural
Vers l'optimisation d'un essai d'aide à la décision en mammographie et d'intervention en communication clinicienne en milieu rural
The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention. This will be accomplished through two aims: (1) Refine, with community partner input, a clinical trial protocol to optimize engagement among patients and primary care providers (PCPs) practicing in rural settings. In consultation with patients, PCPs, and informatics experts, the study team will refine site selection, randomization, patient and PCP recruitment, and data collection protocols to meet the needs of the rural health care delivery system and participants. The result of this aim will be a modified protocol and intervention strategy that is acceptable to partners. (2) Adapt and test trial and intervention implementation features to achieve protocol acceptance and adherence. The investigators will pilot the adapted three-arm randomized trial protocol in rural primary care settings that compares the MyMammogram DA with or without a risk summary provided to the PCP pre-visit, relative to usual care. Implementing the trial in two phases (n=15 each) will systematically identify barriers and facilitators to trial participation to refine protocols. Participants will receive acceptability surveys and investigators will conduct qualitative interviews with patients and PCPs to understand experiences with trial implementation from multiple perspectives.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a three-arm randomized pilot trial that will enroll 30 participants over two study phases. The main objective is to achieve data on trial feasibility (recruitment, retention, randomization, adherence, and acceptability). The primary outcome is Intervention Acceptability.
Procedures: PCPs will be randomized to one of the three arms to prevent contamination across patients (usual care, decision aid, decision aid + clinician communication). Patients will be considered for enrollment if they are aged 40-49, English or Spanish-speaking, have an upcoming primary care visit within 4 weeks, no history of breast cancer, ductal carcinoma in situ, lobular carcinoma in situ, or atypical hyperplasia, and no mammogram within the past 12 months. These patients will be identified via the electronic health record using routine data reports provided to the study team.
Data Collection: Surveys will be conducted at baseline (pre-intervention), post-DA and Post-Visit. Mammography screening information will be collected via medical records, and implementation data will be completed with patients and clinicians who were exposed to the decision aid intervention.
Analysis: All feasibility metrics will be summarized quantitatively, distributions examined for central tendency and spread, and all data assessed for completeness. Data will be presented in a tabular format, with means and standard deviations summarized for the Acceptability of Intervention Measure. Process data will likewise be summarized, reporting proportions of participants meeting each metric (recruitment, retention, randomization, adherence).
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Christine M Gunn, PhD
- Numéro de téléphone: 603-646-5430
- E-mail: Christine.M.Gunn@dartmouth.edu
Lieux d'étude
-
-
New Hampshire
-
Keene, New Hampshire, États-Unis, 03431
- Recrutement
- Cheshire Medical Center
-
Contact:
- Christine Gunn, PhD
- Numéro de téléphone: 603-646-5430
- E-mail: Christine.M.Gunn@dartmouth.edu
-
New London, New Hampshire, États-Unis, 03257
- Recrutement
- New London Hospital Primary Care
-
Contact:
- Christine Gunn
- Numéro de téléphone: (603) 646-5430
- E-mail: christine.m.gunn@dartmouth.edu
-
Newport, New Hampshire, États-Unis, 03773
- Recrutement
- Newport Health Center
-
Contact:
- Christine Gunn
- E-mail: christine.m.gunn@dartmouth.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Patient Inclusion Criteria:
- Females
- Aged 39-49
- Upcoming appointment with a participating primary care provider (within 4 weeks)
- English or Spanish-speaking
Patient Exclusion Criteria:
- Personal history of breast cancer (including lobular carcinoma in situ and ductal carcinoma in situ or atypical hyperplasia)
- Mammogram in the prior 9 months
Clinician inclusion: Any practicing primary care provider at a participating site.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Usual Care
Usual care. |
|
|
Expérimental: MyMammogram
Patient uses MyMammogram prior to appointment. |
An online breast cancer screening decision aid |
|
Expérimental: MyMammogram plus provider communication
Patient uses MyMammogram prior to appointment. Provider receives a summary from MyMammogram prior to appointment. |
An online breast cancer screening decision aid Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Intervention acceptability
Délai: within one day of completing the intervention
|
The acceptability e-scale is a 6-item measure for electronically-delivered interventions, where higher scores indicate greater acceptability. Scores range from 6-30. |
within one day of completing the intervention
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Recruitment feasibility
Délai: 4 weeks
|
Measured as the proportion of eligible participants who receive an initial outreach letter and complete the consent process and enroll prior to their clinical visit. |
4 weeks
|
|
Retention feasibility
Délai: 8 weeks
|
Proportion of participants enrolled who complete all study survey time points, reported per trial arm |
8 weeks
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Knowledge
Délai: enrollment and within one day of completing the intervention
|
10-item measure of breast cancer and screening knowledge that is summed for a score from 0-10 (0 indicates lower knowledge, 10 indicates higher knowledge). |
enrollment and within one day of completing the intervention
|
|
Decisional Quality
Délai: enrollment, within one day of completing the intervention, within one day of completing a clinical visit
|
Decisional Quality is measured using the Decisional Conflict Scale for Low Literacy, a 10-item measure. Scores Range 0-100. Lower scores indicate better decisional quality (lower conflict). |
enrollment, within one day of completing the intervention, within one day of completing a clinical visit
|
|
Screening Intentions
Délai: enrollment, within one day of completing the intervention, within one day of completing a clinical visit
|
Screening intentions are using two methods. 1) As the likelihood of obtaining a mammogram in the next year (5-point Likert scale); and 2) Using 2 items to measure age at which someone intends to begin screening (40, 45, 50, other) and interval (annual, biennial, other). |
enrollment, within one day of completing the intervention, within one day of completing a clinical visit
|
|
Shared Decision-Making
Délai: within one day of completing a clinical visit
|
Shared Decision Making will be assessed with the 3-item, validated CollaboRATE measure. Scored 0-100 (higher scores indicate more shared decision-making). |
within one day of completing a clinical visit
|
|
Self-efficacy
Délai: enrollment and within one day of completing a clinical visit
|
Measured using a validated scale measuring perceived confidence one's personal ability to obtain a mammogram. Ten items are summed, with a theoretical score range from 5-10 (higher scores indicate better self-efficacy). |
enrollment and within one day of completing a clinical visit
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STUDY02002381
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .